VADS Are Ready For Wider Population Trial After REMATCH, Experts Agree
This article was originally published in The Gray Sheet
Executive Summary
The high complication rate associated with Thoratec's HeartMate VE ventricular assist device (VAD) in the seminal REMATCH trial should not deter investigators from testing VADs as a destination therapy in patients less ill than the REMATCH cohort, panelists agreed at an April 10 symposium on trials of mechanical circulatory support in Washington, DC
You may also be interested in...
Thoratec HeartMate A Good Choice For The Very Sick Despite Risks – Panel
Thoratec's HeartMate VE left-ventricular assist system (LVAS) should be made available to end-stage heart failure patients ineligible for a transplant, even though 94% of patients treated with the LVAS in clinical trials experienced a serious adverse event, FDA's Circulatory System Devices Panel agreed
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.